PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

San Antonio, TX US

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
  • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
  • Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
  • Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
Additional information

Supported by educational grants from AstraZeneca and Pfizer. Supported by an independent educational grant from TESARO.

Course summary
Available credit: 
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
Course expires: 

Agenda (all times listed are Central Standard Time)

8:00 PM - Welcome and Introduction

8:05 PM - Understanding the Rationale and Mechanism of Action for PARP Inhibition in MBC

8:25 PM - Integrating PARP Inhibition Into Clinical Management of Patients With MBC

8:55 PM - Future Directions in PARP Inhibitors in Breast Cancer: Where Do We Go From Here?

9:20 PM - Final Thoughts and Audience Question and Answer Session

San Antonio Marriott Rivercenter
101 Bowie Street
Grand Ballroom, Salons EF
San Antonio, TX 78205
United States

Lee Schwartzberg, MD, FACP
Executive Director 
West Cancer Center
Germantown, Tennessee
Chief, Division of Hematology/Oncology
Professor of Medicine
University of Tennessee Health Science Center
Memphis, Tennessee

Judy E. Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Chief, Division of Cancer Genetics and Prevention
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.

The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Judy E. Garber, MD, MPH, has disclosed that she has received funds for research support from Ambry Genetics, AstraZeneca, and Myriad Genetics and has received consulting fees from Helix Genetics and that her spouse has served on advisory boards for Oric Pharmaceuticals, has received consulting fees from GTx Pharmaceuticals and Novartis Oncology, and has received funds for research support from Novartis Oncology.

Mark E. Robson, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, BioMarin, and Medivation and consulting fees from AstraZeneca and McKesson.

Lee Schwartzberg, MD, FACP, has disclosed that he has served as a scientific advisor for Bristol-Myers Squibb Company and has received consulting fees/honoraria from Genentech, Genomic Health, and Pfizer.

The activity planning staff listed below discloses no relevant financial relationships:
CCO: Timothy Quill, PhD; Gordon Kelley; Rachael M. Andrie, PhD; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CMP, CHCP

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.5 contact hours.


The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: 0836-9999-18-132-L01-P

Available Credit

  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing